

### COMPANY PROFILE

NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics:

- Spiegelmer<sup>®</sup> NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) which is implicated in diabetic complications including nephropathy. NOX-E36 is currently completing a Phase Ib study in healthy subjects and diabetics, and a Phase IIa diabetic nephropathy study is currently in preparation.
- Spiegelmer<sup>®</sup> NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of tumor invasion, metastasis and resistance to chemotherapy, and has completed Phase I. Clinical Trial Applications have been submitted for Phase IIa studies in two hematological oncology indications.
- Spiegelmer<sup>®</sup> NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease, and is currently in a comprehensive single and multiple ascending dose Phase I study. Two human efficacy trials of NOX-H94 are currently in preparation.

The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.

### RECENT NEWS


- **01/2012:** NOXXON to present at 30th annual J.P. Morgan Healthcare conference
- **12/2011:** NOXXON's SDF-1 inhibitor NOX-A12 completes Phase I
- **09/2011:** NOXXON initiates NOX-H94 Phase I, third Spiegelmer to enter clinic
- **02/2011:** NOXXON appoints Dr. Matthias Baumann as Chief Medical Officer
- **10/2010:** NOXXON confirms total capital raise of €35m

more news on [www.noxxon.com](http://www.noxxon.com)

### NOXXON 2012 MILESTONES

- NOX-H94 Proof-of-principle study in healthy volunteers completion: 2Q-2012
- NOX-E36 Phase IIa study in diabetics with nephropathy, interim assessment 3Q-2012
- NOX-H94 Phase II study in anemia of chronic disease patients, initiation: 3Q-2012
- NOX-A12 Phase I/II study of in haematological cancer patients, interim assessment 4Q-2012

### PIPELINE



### SENIOR MANAGEMENT

**Iain Buchanan**

Chief Executive Officer

**Dr. Matthias Baumann**

Chief Medical Officer

**Dr. Sven Klussmann**

Chief Scientific Officer

**Aram Mangasarian, PhD**

Chief Business Officer

**Dr. Heike Balzer**

Senior Vice President, Finance

**Dr. Dirk Eulberg**

Vice President, Project Management

**Dr. Frank Fliegert**

Vice President, Clinical Drug Development

**Karen Christine Ophoff**

Vice President, Legal Affairs, General Counsel

**Dr. Axel Vater**

Vice President, Drug Discovery

**Dr. Stefan Vonhoff**

Vice President, CMC

### SUPERVISORY BOARD

**Dr. Walter Wenninger**

Chairman of the Supervisory Board

### ■ FINANCIAL SUMMARY

NOXXON closed a €35 million Series D round of financing in Sept 2010. The round was led by new investor, NGN Capital, joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VCFonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, CD Ventures and others.

### ■ PRODUCTS IN CLINICAL DEVELOPMENT

NOXXON focuses on the development of Spiegelmers for the treatment of inflammatory diseases and hematological disorders. NOXXON's projects are characterized by highly promising targets and clear clinical objectives. Each project addresses a significant unmet medical need.

**Spiegelmer® NOX-E36** is the first of NOXXON's programs – a Spiegelmer active against MCP-1 (Monocyte Chemoattractant Protein 1)/ CCL2 (Chemokine (C-C motif) ligand 2) for the treatment of complications arising from diabetes, including nephropathy. NOX-E36 has shown activity in animal models of diabetic nephropathy, lupus nephritis and COPD (chronic obstructive pulmonary disease). The target of NOX-E36, MCP-1, has also recently been shown to be an important target in tumor metastasis. NOX-E36 successfully completed a Phase Ia safety trial in healthy volunteers and is now in a dose escalation Phase Ib trial, which includes diabetic patients treated for one month.

**Spiegelmer® NOX-A12**, NOXXON's second clinical candidate, targets SDF-1: Stromal Cell-Derived Factor-1 / CXCL12 : Chemokine (C-X-C motif) ligand 12, a chemokine mediator of invasiveness, metastasis and resistance to chemotherapy in cancer. NOX-A12 has completed Phase I studies and has shown promising activity in pre-clinical models of hematological and solid tumors. Clinical Trial Applications have been submitted for Phase IIa studies in two hematological oncology indications and clinical trials in solid tumors are under discussion with experts and regulatory authorities.

**Spiegelmer® NOX-H94**, the third clinical program, is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism. Hepcidin is up-regulated by acute and chronic inflammatory reactions resulting in "iron restriction", which means that iron is blocked inside cellular stores and not available for hemoglobin synthesis. This is in contrast to "iron deficiency", in which iron stores are depleted. NOX-H94 is currently in a comprehensive, two stage Phase I trial in which iron mobilization has been demonstrated. NOXXON plans to initiate two clinical efficacy studies in 2012.

### ■ PRECLINICAL PROGRAMS

In addition, NOXXON has generated Spiegelmers in other disease areas including inflammation (the complement component C5a), cancer (Sphingosine-1-phosphate / S1P) and diabetes (Glucagon).

NOXXON is also exploring applications of certain Spiegelmers as therapy in the area of ophthalmology. Spiegelmers appear to be particularly well suited to local administration into the eye with good tolerance and a long intra-vitreous half-life.

### ■ INTELLECTUAL PROPERTY

NOXXON has pursued an aggressive patent and licensing strategy making the Spiegelmer Technology one of the best protected drug discovery platforms in the industry. NOXXON's intellectual property (IP) comprises a) an exclusive license to the SELEX process for screening of nucleic acid libraries to make Spiegelmers for therapeutic applications, b) patents covering mirroring technologies, c) Spiegelmer modification patents that improve the substance class' versatility, and d) composition of matter patents for Spiegelmer products. The IP estate includes over 340 patents and patent applications, ensuring full freedom to operate for NOXXON and its partners.

### CORPORATE HEADQUARTERS

**NOXXON Pharma AG**  
Max-Dohrn-Strasse 8-10  
10589 Berlin  
Germany

Phone: +49 30 726 247 0  
FAX: +49 30 726 247 225  
Web: [www.noxxon.com](http://www.noxxon.com)

### GENERAL AND MEDIA CONTACT

Emmanuelle Delabre  
Phone: +49 30 726 247 100  
FAX: +49 30 726 247 225  
Email: [edelabre@noxxon.com](mailto:edelabre@noxxon.com)

### BUSINESS DEVELOPMENT

Aram Mangasarian, PhD  
Phone: +49 30 726 247 0  
FAX: +49 30 726 247 225  
Email: [amangasarian@noxxon.com](mailto:amangasarian@noxxon.com)

The sole purpose of this fact sheet is to describe the business activities of NOXXON Pharma AG ("the Company"). This document does not itself constitute or form part of an offer of, or an invitation to purchase any shares in the Company. Neither this document nor any part of it nor the fact of its distribution forms the basis of, or should be relied on in connection with, any contract for the purchase of any shares or for any purpose whatsoever. The Company has not authorized any person to provide third parties with any information, or to make any representation, concerning the offering of any shares in the Company. The delivery of this document shall not under any circumstances imply that information contained herein is correct as at any time subsequent to the date hereof or that there has been no change in the affairs of the Company since the date hereof. No representation or warranty, expressed or implied, is given as to the accuracy of the information or opinions contained in this document and no liability is accepted for any such information or opinion.

Status January 2012